Specialty pharmaceutical firm Warner Chilcott priced its large 70.6 million share offering at $15, a 17% discount to its proposed $17-$19 range, on Wednesday evening. Warner Chilcott, a spin-off of Warner Lambert (now Pfizer), is engaged in the acquisition and development of branded prescription drugs in the US with a focus on women’s healthcare and dermatology. Goldman Sachs, Credit Suisse, J.P. Morgan and Morgan Stanley were joint book-running managers on the deal. The stock is expected to commence trading on the NYSE under the ticker symbol "WCRX" on Thursday.
